ProStrakan is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.  

With approximately 200 people employed in the Company's operations, ProStrakan is headquartered in Scotland with commercial operations throughout the rest of the UK and continental Europe. In R&D, the Company's Development group is located at Galashiels in Scotland.

In June 2005, ProStrakan completed its initial public offering (IPO) of shares to become listed on the London Stock Exchange.

 Our aim is to alleviate the often distressing symptoms associated with hitherto poorly treated conditions.  We will achieve this by introducing novel and effective prescription medicines to the market, in the process creating a significant international pharmaceutical business.

In addition to rapid organic growth, our business model (see Strategy) allows for growth through acquisitions and mergers. M&A activity has featured prominently in the company’s recent past.

Our broad R&D portfolio covers projects from early research right through clinical trials and on to registration and marketing.

2006:
- Sale of Drug Discovery Unit (formerly ProSkelia)
- Zindaclin out-licensed to Crawford Healthcare
- Cellegy asset acquisition (Tostran and Rectogesic, USA)
- Collaboration with Novartis (bone)
- Collaboration with Amgen (renal)

2005:
- Rapinyl in-licensed
- Tostran launched (Tostrex, Sweden)
- Flotation on the LSE
- Rectogesic in-licensed (EU)
- APS Pharma acquired (Germany)

2004:
- Strakan / ProSkelia merged
- OTL Pharma acquired (Paris)
- Elfar and Devon Farmacéutica acquired (Spain)
- Tostran in-licensed (EU)

2001:
- Isotard in-licensed

2000:
-OTL Pharma founded

1999:
- Adcal D3 in-licensed

1995:
- Strakan founded by Harry Stratford and Prof John Kanis

• Experienced and respected management
  
• Rapidly growing pharmaceutical company with cutting edge R&D organisation and strong commercial platform
  
• Extensive R&D portfolio, minimising risk and maximising opportunity
  
• Expanding European commercial operations
  
• Growing revenue from sales
  
• A range of products on EU markets

In 2004, ProStrakan’s revenues from product sales in Europe nearly trebled over figures for the previous year, making ProStrakan one of the fastest growing pharmaceutical companies in the UK. In 2005, this continued with growth in product sales of 46%.